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The bacteriological and clinical efficacy and the safety of gatifloxacin for the treatment of non-
complicated acute rhinosinusitis was evaluated in 49 adult patients in an open-label multicenter
study in Brazil. Patients under age 18, or with associated systemic diseases, were excluded.
Diagnosis was based on symptoms, otorhinolaryngological examination, and X-rays of the sinus.
At the first visit, all patients were treated with a single daily dose of 400 mg gatifloxacin for 10
days. Middle nasal meatus secretion was collected and sent for culture before and after treatment.
Patients were all reevaluated at days 3 to 5; days + 1 to + 5 and 18 to 25 days + 7 to + 14 . Ninety
three percent of the patients were considered clinically cured at the end of the treatment. The
most frequent bacteria isolated were Haemophilus influenzae, Streptococcus pneumoniae and
Moraxella catarrhalis, and at the end of the treatment, presumed bacteriological eradication was
observed in almost all patients. Adverse effects were observed in 19 of the cases, mostly mild and
self limiting, including diarrhea, abdominal pain, nausea and vomiting. Treatment had to be
interrupted in two cases. Gatifloxacin was found to be efficacious and safe for the treatment of
acute rhinosinusitis in adults.
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Rhinosinusitis, an inflammatory disease, is one of the
most commonly reported diseases of the sinus. It is
estimated that in the United States about 35 million
individuals suffer from at least one episode of acute
rhinosinusitis each year. There have been reports of
increasing prevalence of this disease along the years,
causing many lost workdays [1].
According to periodic national physician surveys,
chronic rhinosinusitis is responsible for approximately 11.6
million office visits per year. In addition, rhinosinusitis has
been considered one of the five main motives for antibiotic
prescriptions. In 1992, 13 million antibiotic prescriptions
were made to treat acute and chronic rhinosinusitis [2].
The differential diagnosis of a viral or a bacterial
infection is not always simple, although it is essential
for optimum management. Antibiotics have been
systematically recommended to treat bacterial sinus
infections, in order to prevent both recurrences and
complications, such as periorbital cellulitis, epidural
and subdural empyemas, and, less frequently,
osteomyelitis, meningitis, and thrombosis of the
cavernous sinus [3].
.
Diagnosis of acute rhinosinusitis is normally based
on signs and symptoms, which are usually
characterized by persistent (10 to 30 days duration)
nasal obstruction, headache, cough, fever, and
mucopurulent discharge from the middle nasal meatus.
Intense and severe initial symptoms may also indicate
acute bacterial infection. The bacteria involved in the
etiology of more than 70% of the cases of acute
rhinosinusitis in adults and in children, worldwide, are
Streptococcus pneumoniae and Haemophilus
influenzae. Less frequently, Moraxella catarrhalis,
Staphylococcus aureus and β- hemolytic
Streptococcus are also involved. The emergence of
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resistance and of variations in the antibiotic
susceptibilities of the causative bacteria poses a great
challenge to health care professionals who need to
select the appropriate antibiotic [3].
Gatifloxacin is a new broad-spectrum synthetic
fluoroquinolone that has proven to be safe and effective
for the treatment of community-acquired respiratory-
tract infections. Gatifloxacin has demonstrated antibiotic
activity against S. pneumoniae, H. influenzae, M.
catarrhalis, S. aureus, Klebsiella pneumoniae,
Chlamydia pneumoniae, Legionella pneumophila
and Mycoplasma pneumoniae. Its half-life of eight
hours permits a once a day regimen [4].
.
 We examined
the bacteriological and clinical efficacy and the safety
of gatifloxacin in the treatment of non-complicated
acute rhinosinusitis in adults.
Material and Methods
We report on the Brazilian data of an open-label
international multicenter study, carried out in 15 centers:
four in Brazil, eight in Mexico and three in Thailand. In
Brazil, the study was previously submitted to and
approved by the ethics committees of the four
participating centers. Forty-nine adult patients with acute
non-complicated bacterial rhinosinusitis were evaluated.
To be eligible for enrollment in this study, subjects had
to meet all of the following criteria:
· Male or female, 18 years of age or older;
· Signs and symptoms consistent with an acute
maxillary sinus infection: facial pain/tenderness of
one or both maxillary areas, and at least one of
the following symptoms: purulent discharge from
a maxillary sinus orifice, purulent discharge from
the nose, or a postnasal purulent discharge;
· Radiologic confirmation of maxillary sinusitis: when
at least one of the following signs were observed
in one or both maxillary sinuses: opacification,
visible air/fluid level, or mucosal thickening > 5mm.
Exclusion criteria included chronic, recurrent and
complicated sinus infection, anatomic abnormalities of
the nose and paranasal sinuses, history of sinus surgery,
nosocomial sinus infections or infections following or
associated with nasotracheal intubation, cystic fibrosis,
renal insufficiency, immunodeficiency, mal-absorption
syndromes, pregnancy or breast feeding, and use of
antibiotics within the previous 48 hours. All female
subjects received orientation regarding the importance
of avoiding pregnancy and of adequate birth control.
All patients received 400 mg gatifloxacin, once a
day for 10 days. No other/concurrent antibiotic or
anti-inflammatories were allowed as part of the
treatment. Middle nasal meatus discharge, if present,
was collected before and after treatment, under
endoscopic visualization, by using a suction-collector.
The material was immediately sent to the laboratory
for Gram staining, culture and antimicrobial
susceptibility testing.
Eligible subjects for primary efficacy analysis of the
clinical response included those who had received at
least five days of treatment with the study drug (at least
three days for failures) and who completed the study.
The clinical response was evaluated according to
the following criteria:
Cure
Resolution of the acute clinical signs and symptoms
relevant to the original sinus infection at the end of
treatment (day +1 to day + 5) and/or no need for
antibiotic treatment at post-treatment evaluation. (day
+ 7 to day + 14 ).
Failure
Lack of improvement of signs and symptoms of the
acute sinus infection after at least three days of
gatifloxacin therapy.
Relapse
Those patients with complete resolution of the acute
signs and symptoms relevant to the original sinus
infection at the end of treatment (day +1 to +5), but
who then developed symptoms in the post-treatment
period (day + 7 day to +14).
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Unable to determine
Extenuating circumstances precluded classification
as cure, failure or relapse.
 Bacterial response was defined as: documented
eradication, when the pathogenic bacteria isolated at
the beginning of the treatment were not present at the
end of the treatment; presumed eradication, when the
patient presented clinical cure but a culture was not
available; documented persistence, when the pathogenic
bacteria were isolated at the end of the treatment;
presumed persistence, when a clinical failure occurred
but culture was not available; or undetermined, when
the clinical parameter was undetermined.
Safety evaluation analysis was performed on all
patients who had received at least one dose of the
medication. It was based on the occurrence of adverse
events and clinically important changes in laboratory
parameters. Particular attention was given to those
events that resulted in discontinuation of the study drug,
or which were serious in nature. Adverse events were
monitored at each follow-up visit.
Blood and urine samples were obtained for
laboratory testing at the pretreatment visit, during
treatment (if clinically indicated) and at the end of the
treatment.
Results
Forty-nine subjects were enrolled in the Brazilian
arm of the study. Most (80%) of the patients were
Caucasian, and male (65%). Ages ranged between 18
and 68 years, with a median age of 33.
The most frequently observed signs and symptoms
of acute rhinosinusitis were purulent nasal discharge
(94%), nasal obstruction (90%), headache (90%), and
facial pain (71%) (Table 1).
Clinical efficacy
Almost all patients presented resolution or marked
improvement of their symptoms; 44 of the 49 patients
were considered cured at the end of the treatment (day
+1 to day +5 ). One patient presented worsening of
the symptoms, and antibiotic therapy was prescribed
in another. It was not possible to determine the clinical
response of four patients; two of them discontinued
the medication due to adverse events and two were
lost to follow-up (Table 2). Forty patients returned for
the last visit (day +7 to +14), and 39 out of the 49
were defined as cured. The cure rate at the last follow-
up visit was 80%.
Bacteriological study
Cultures were obtained from the nasal secretion of
36 patients, and the most frequently isolated pathogenic
bacteria were H. influenzae (16), S. pneumoniae (13)
and M. catarrhalis (5) (Table 4). More than one type
of bacteria was isolated in the cultures of 10 patients,
and the most frequent association was H. influenzae/S.
pneumoniae (four patients). Table 5 shows the
relationship between clinical efficacy and the type of
bacteria isolated in the inclusion visit and the high clinical
cure percentage for the most frequently isolated bacteria.
The results of the bacterial eradication efficacy can be
observed in Table 6. Most of the bacteria that were
isolated were susceptible to gatifloxacin. Presumed
eradication was observed in most patients. In two cases,
the analysis of the treatment efficacy was undetermined,
and one patient presented failure of treatment.
Adverse events
Forty-nine patients received at least one dose of
gatifloxacin and were evaluated for safety. Adverse events
judged as certain, probably, or possibly related to the
study drug were observed in 19 out of 49 patients (39%).
They were mostly mild gastro-intestinal problems,
including diarrhea in eight (16%), abdominal pain in five
(10%), vomiting in four (8%) and nausea in four (8%)
(Table 3). Medication was discontinued in two cases;
one patient experienced a severe allergic reaction, with
glottic edema on the second day of treatment, and was
treated with I.V. corticosteroids; the other discontinued
the treatment on the sixth day due to intense abdominal
pain. Both patients experienced complete recovery.
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Table 1. Signs and symptoms of the gatifloxacin study group (n=49)
Table 2. Results of clinical efficacy day +1 to + 5, end of treatment and (day + 7 to + 14) final visit
Table 3. Adverse events considered to have a certain, probable or possible relationship to the study drug (n=49)
Use of Gatifloxacin in the Treatment of Rhinosinusitis
Signs and symptoms* N % Signs and symptoms* N %
Purulent nasal discharge 46 94 Halitosis 18 37
Nasal congestion 44 90 Sore throat 14 29
Headache 44 90 Dental pain 10 20
Face pain 35 71 Watery nasal discharge 9 18
Sinus pain 35 71 Tenderness of the sinus 7 14
Coughing 34 69 Chills 2 4
Hyposmia 31 63 Epistaxis 1 2
Postnasal drip 31 63 Hoarseness 1 2
Face pressure 28 57 Ear pain 1 2
Malaise 23 47 Swollen sinus 1 2
Fever 22 45
* A subject may have more than one sign/symptom.
 V3 V4
 D+1/D+ 5 D+7/D+14
N % N %
Cure 44  90 39 80
Failure 1 2 1  2
Recurrence - - - -
Undetermined 4  8 9 18
Total 49 100 49 100
Adverse event N %
Any body system 19 40
Allergic reaction 1 2
Headache 1 2
Digestive system 15 31
Constipation 1 2
Diarrhea 8 16
Flatulence 1 2
Nausea 4 8
Abdominal pain 5 10
Vomiting 4 8
Nervous system 5 10
Dizziness 3 6
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Table 4. Type of bacteria isolated before treatment (day +1/D +5)
Table 6. Results of bacteriological efficacy according to the isolated bacteria
Table 5. Relationship between clinical efficacy and type of isolated bacteria before treatment (day +1 to day +5)
Use of Gatifloxacin in the Treatment of Rhinosinusitis
Bacteria  N %
H. influenzae 16 36
S. pneumoniae 13 30
M. catarrhalis 5 12
S. aureus 3 7
E. coli 1 2
E. aerogenes 1 2
Proteus retigeri 1 2
Neisseria spp. 1 2
Total 44 100
Cure Failure Undetermined
N % N % N %
H. influenzae 15/16 94 0/16 0 1/16 6
S. pneumoniae 12/13 92 1/13 8 0/13 0
M. catarrhalis 5/5 100 0/5 0 0/5 0
S. aureus 2/3 67 0/3 0 1/3 33
Streptococcus spp. 1/1 100 0/1 0 0/1 0
S. pyogenes 2/2 100 0/2 0 0/2 0
E. coli 1/1 100 0/1 0 0/1 0
E. aerogenes 1/1 100 0/1 0 0/1 0
Proteus retigeri 1/1 100 0/1 0 0/1 0
Neisseria spp. 1/1 100 0/1 0 0/1 0
Documented Presumed Presumed
Eradication Eradication Persistence
N % N % N %
H. influenzae 1/16 6 15/16 94 0/16 0
S. pneumoniae 0/13 0 12/13 92 1/13 8
M. catarrhalis 0/5 0 5/5 100 0/5 0
S. aureus 0/3 0 2/3 67 0/3 0
S. pyogenes 0/2 0 2/2 100 0/2 0
Streptococcus sp 0/1 0 1/1 100 0/1 0
E. coli 0/1 0 1/1 100 0/1 0
E. aerogenes 0/1 0 1/1 100 0/1 0
Proteus retigeri 0/1 0 1/1 100 0/1 0
Neisseria spp. 0/1 0 1/1 100 0/1 0
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Discussion
The diagnosis of rhinosinusitis is often presumptive,
and consequently treatment is empirical. The
emergence of resistant causative bacteria is a
worldwide concern and poses a great challenge for
selecting effective antibiotics. Although a large
percentage of patients with sinusitis are known to
recover spontaneously, antibiotics have been
systematically recommended in the treatment of
confirmed cases of bacterial rhinosinusitis. Currently, a
large selection of antibiotics is commercially available
and indicated by international guidelines for the treatment
of acute bacterial rhinosinusitis [1]. International
guidelines indicate, amoxicillin, amoxicillin-clavulanate,
cefaclor, azithromycin, clarithromycin, axetil-
cefuroxime, cefprozil, cefpodoxime-proxetil,
levofloxacin, moxifloxacin and gatifloxacin [3]. 
.
The dilemma facing many physicians is how to select
the most appropriate antibiotic from a variety of
pharmacological options. According to the American
Academy of Otolaryngology Committee, which is
responsible for rhinosinusitis recommendations, several
criteria should be considered; previous clinical trial
results, regional differences in resistance patterns,
antimicrobial activity against resistant pathogens, dosing
facility, adverse effects, history of allergy, and cost [1].
Considering all these factors, gatifloxacin has shown
to be a very attractive choice for the treatment of acute
bacterial rhinosinusitis in adults. Gatifloxacin clinical
efficacy has been demonstrated in many studies and
clinical trials, and it has shown excellent in vitro activity
against the most frequent respiratory tract infection
pathogens, including penicillin-resistant bacteria, such
as S. pneumoniae [5,6].
Gatifloxacin allows an easy to schedule dosage.
Most of the reported adverse events are mild, and costs
are similar to that of other antibiotics recommended
for the treatment of rhinosinusitis.
Gatifloxacin, provided once a day for 10 days, gave
clinical and bacteriological efficacy. Although ours was
not a comparative study, other studies have reported
similar results. A multicenter-randomized double blind
comparative study between gatifloxacin and
clarithromycin for the treatment of acute maxillary
bacterial rhinosinusitis indicated similar clinical efficacy
of the two drugs and better tolerability of gatifloxacin
[7]. Another study comparing gatifloxacin and
amoxicillin-clavulanate, as treatments for acute
rhinosinusitis, demonstrated equivalent bacterial efficacy
against H. influenzae, S. pneumoniae, and S.
pyogenes, and superior efficacy against M. catarrhalis
and S. aureus [8].
.
Several international epidemiological surveillance
studies, including the SENTRY antimicrobial
surveillance program, in which Brazil has had a large
participation, have consistently demonstrated an
annually-increasing rate of infection with isolates of S.
pneumoniae that have diminished susceptibility to
penicillin, cephalosporins and macrolides [9]. However,
susceptibility to gatifloxacin among these isolates has
been 100%, including highly penicillin-resistant S.
pneumoniae. All strains of H. influenzae and M.
catarrhalis have also been found to be susceptible to
gatifloxacin, proving it to be more efficient than
amoxicillin/clavulanate and other antibiotics [10].
Only one serious adverse event was observed,
leading to interruption of the treatment. The absence
of photo-sensitivity is an important point, since this is a
relatively common adverse effect reported for other
fluorquinolones, such as moxifloxacin
 
[11,12]. Our
study confirms other previous trials, indicating that
gatifloxacin is well tolerated, since most of the adverse
effects were mild, essentially involving gastric-enteric
disturbances .
In conclusion, the efficacy and safety profile that
we found for gatifloxacin supports our recommendation
of this antibiotic as an appropriate option for the
treatment of bacterial rhinosinusitis in adults.
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